Metastatic disease to the pelvis can lead to structural instability and debilitating pain. Lesions are often quite large at the time of diagnosis, as the size of the pelvis and elastic nature of the peri-pelvic organs often result in few symptoms of mass effect for smaller lesions. Lesions ...
Newer hormonaldrugsthat decrease androgen production (abiraterone) and block androgen receptor signaling (enzalutamide) have been approved by the FDA for the treatment of metastatic prostate cancer following chemotherapy, and they are being studied for early usage in the disease. Abiraterone Abiraterone is...
The life expectancy of Western populations has risen in the last few decades, resulting in a steep increase in the number of elderly cancer patients. Metas... Vassiliou,Vassilios - 《Clinical Oncology》 被引量: 37发表: 2013年 加载更多研究点推荐 Bone metastases Metastatic Bone Disease bone metast...
the spread of a disease-producing agency (such as cancer cells) from the initial or primary site of disease to another part of the bodyalso: the process by which such spreading occurs metastasis of breast cancer to bone—Medical Physics ...
We explore the diversity of technologies and targeting approaches that have been investigated to enhance the delivery of a range of complex cargoes, in the treatment of primary cancers and metastatic bone disease, with a view to summarising the benefits, limitations and current state of progress of...
Bone is one of the most common metastatic areas in the cancer patient. Bone metastasis is the major cause to deteriorate the quality of life due to severe pain, walking difficulty, paraplegia, and pathologic fracture. To maintain patient’s general condi
not more than one prior chemotherapy regimen for metastatic disease; no prior exposure to either taxanes or 5-FU administered as a continuous infusion; World Health Organization (WHO) performance status of 0, 1, or 2; life expectancy >12 weeks; not pregnant and using effective contraception if...
Tumor assessment was carried out using enhanced CT scan (covering neck, thorax, and abdomen), bone ECT at baseline and every 6 weeks during the treatment and follow-up period for PFS. Patients were followed up for survival status every 12 weeks after disease progression or initiation of new ...
Metastasis was confirmed by positive bone scan, MRI, CT or biopsy, and death certificates confirmed cause of death. Results We detected 15 recurrent CNAs were associated with metastasis in the FH cohort and replicated in the EV cohort (p < 0.05) without adjusting for Gleason score in the...
We propose a deep learning model - Probabilistic Prognostic Estimates of Survival in Metastatic Cancer Patients (PPES-Met) for estimating short-term life expectancy (>3 months) of the patients by analyzing free-text clinical notes in the electronic medical record, while maintaining the temporal visi...